Corcept Therapeutics IncorporatedNASDAQ: CORT

Corcept's (CORT) pipeline progress has been encouraging with relacorilant currently under evaluation for Cushing's syndrome. The NDA for relacorilant is expected to be filed in the third quarter.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Corcept (CORT) exceeds expectations for both earnings and sales in the first quarter of 2024. The company raises its revenue forecast for the full year.

Corcept Therapeutics Incorporated (NASDAQ:CORT) held its Q1 2024 Earnings Conference Call on May 1, 2024 at 5:00 PM ET. Company representatives present included Atabak Mokari, Charlie Robb, Joe Belanoff, William Guyer, and Sean Maduck. Conference call participants included Matt Kaplan, David Amsellem, and Swayampakula Ramakanth. The operator welcomed everyone on the call.

Corcept (CORT) could see an increase in its stock price due to increasing confidence in its earnings potential, as indicated by its upgrade to a Zacks Rank #1 (Strong Buy).

The DAZALS study phase II is assessing Corcept's (CORT) dazucorilant for the treatment of amyotrophic lateral sclerosis. Recruitment for the study has finished.

The ROSELLA study phase III is assessing Corcept's (CORT) relacorilant in combination with nab-paclitaxel for the treatment of recurrent ovarian cancer that is resistant to platinum-based therapy. The study has finished enrolling participants.

Corcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to generate incremental sales and combat stiff competition.

Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024.